surf1944
17 years ago
SGX Provides Update on BCR-ABL Collaboration
SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) today provided an update on its license and collaboration agreement with Novartis focused on the development and commercialization of BCR-ABL inhibitors for the treatment of both first line and drug resistant Chronic Myelogenous Leukemia (CML).
Under the collaboration, SGX and Novartis are progressing a number of potential drug candidates, with the anticipated timeline for filing an IND of the second half of 2008, contingent upon the successful completion of further preclinical studies, including formal toxicology studies and drug formulation studies.
One of the candidates from the collaboration, SGX393, is a potent inhibitor of the T315I mutant (as well as other drug resistant mutants and wild type BCR-ABL) and has its most likely application in drug resistant CML. Pursuant to an amendment to the license and collaboration agreement, SGX has obtained the right to develop and commercialize SGX393 outside of the collaboration, subject to a reacquisition right of Novartis that is exercisable at a future date. In addition, the amendment gives Novartis responsibility for the selection of all future development candidates as well as responsibility for the clinical development of additional compounds from the collaboration. The financial terms of the collaboration agreement remain unchanged.
The amendment is intended to maximize the potential output of the Novartis-SGX collaboration. Going forward, collaboration efforts will continue to focus on drug candidates that have potential for front-line usage. SGX now has the additional opportunity to bring forward a molecule in SGX393 which provides the potential for accelerated approval in the drug resistant CML patient population for which there are limited treatment options. The anticipated timeline for filing an IND on SGX393 is the first half of 2008, contingent upon the successful completion of further preclinical studies, including formal toxicology studies and drug formulation studies.
'We are pleased with the progress under our collaboration with Novartis,' said Mike Grey, President and Chief Executive Officer of SGX. 'With the collaboration focusing on potential front-line candidates and SGX moving SGX393 forward, we now have multiple opportunities being progressed in parallel for this important disease area.'
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its enabling, proprietary FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors currently being developed in partnership with Novartis, MET tyrosine kinase inhibitors, including SGX523, and potent JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.
Forward-looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to research and development programs, expectations regarding the timing of the filing of INDs, the potential of the Company's inhibitors as treatments for certain cancers and the ability to discover, develop and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs or commence clinical studies in the referenced time frames. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2006, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
SOURCE SGX Pharmaceuticals, Inc.
Source: PR Newswire (September 10, 2007 - 3:46 PM EST)
News by QuoteMedia
surf1944
17 years ago
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2007
SAN DIEGO, Aug. 8 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced financial results for the three and six months ended June 30, 2007. For the three months ended June 30, 2007, the Company posted revenues of $8.5 million and a net loss of $4.0 million. For the six months ended June 30, 2007, revenues were $19.5 million and the net loss was $5.1 million. Cash, cash equivalents and short-term investments totaled $28.1 million at June 30, 2007 as compared to $33.9 million at December 31, 2006.
'We are pleased with our research and development achievements this past quarter,' said Mike Grey, President and Chief Executive Officer. 'The development of SGX523, our MET tyrosine kinase inhibitor, remains on track, and we are continuing to evaluate partnering opportunities in connection with our MET program. In addition, we are continuing to advance a number of compounds in our BCR-ABL program for the treatment of chronic myelogenous leukemia with the goal of filing an IND in the first half of 2008.'
Financial Results for the Three and Six Months Ended June 30, 2007
Total revenues for the three months ended June 30, 2007 were $8.5 million, compared to $7.8 million for the three months ended June 30, 2006. Total revenues for the six months ended June 30, 2007 were $19.5 million, compared to $12.6 million in the six months ended June 30, 2006. The increase of $0.7 million for the three month period, and $6.9 million for the six month period, was primarily due to the reimbursement of development costs related to our collaboration with Novartis, together with the achievement of a milestone, and additional services provided, under other commercial agreements. The increase for the six month period ended June 30, 2007 also reflects the recognition of revenue in the first quarter of 2007 related to the reimbursement of overhead costs incurred on grant research efforts since the commencement of the grant in July 2005.
Research and development expenses for the three months ended June 30, 2007 and 2006 were $10.5 million and $15.0 million, respectively. Research and development expenses for the six months ended June 30, 2007 and 2006 were $20.5 million and $27.0 million, respectively. The decrease of $4.5 million for the three month period, and $6.5 million for the six month period, was primarily attributable to lower development costs associated with clinical trial activities, partially offset by additional costs incurred in connection with the research and development activities in our oncology pipeline.
General and administrative expenses for the three months ended June 30, 2007 and 2006 were $2.1 million and $2.5 million, respectively. General and administrative expenses for the six months ended June 30, 2007 and 2006 were $4.4 million and $5.6 million, respectively. The decrease of $0.4 million for the three month period, and $1.2 million for the six month period, was primarily attributable to a decrease in non-cash stock-based compensation expense, together with a decrease in recruiting expenses, professional services and other administrative costs.
SGX reported a net loss attributable to common stockholders for the three months ended June 30, 2007 of $4.0 million, or $0.26 per share. This compares with a net loss attributable to common stockholders for the three months ended June 30, 2006 of $9.4 million, or $0.62 per share. For the six months ended June 30, 2007, the net loss attributable to common stockholders was $5.1 million, or $0.33 per share. This compares with a net loss attributable to common stockholders for the six months ended June 30, 2006 of $19.8 million, or $1.60 per share.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The SGX oncology pipeline includes drug candidates from its enabling, proprietary FAST(TM) drug discovery platform, such as next generation BCR-ABL inhibitors currently being developed in partnership with Novartis, MET tyrosine kinase inhibitors, including SGX523, and potent JAK2 inhibitors. More information on the pipeline and drug discovery platform can be found at http://www.sgxpharma.com and in the Company's various filings with the Securities and Exchange Commission.
Forward-looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to research and development programs, plans for 2007 and 2008, expectations regarding the timing of the filing of INDs, the potential of the Company's inhibitors as treatments for certain cancers, partnering opportunities for the Company's research and development programs and the ability to discover, develop and commercialize cancer therapeutics. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file INDs or commence clinical studies in the referenced time frames. The results of early preclinical studies or clinical trials may not be predictive of future results, and the Company cannot provide any assurances that any of its compounds or development candidates will have favorable results in preclinical studies or future clinical trials. In addition, results may be affected by risks related to the implementation of its collaborations, the partnering of its research and development programs, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, the level of resources that its collaborative partners devote to development of its product candidates, the scope and validity of patent protection for its products, and its ability to obtain additional funding to support its operations. For a discussion of these and other factors, please refer to the risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2006, the Company's quarterly report on Form 10-Q for the three months ended March 31, 2007, as well as other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and SGX undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Contact: Todd Myers Jason Spark
Chief Financial Officer Media & Investor Relations
SGX Pharmaceuticals Porter Novelli Life Sciences
(858) 558-4850 (619) 849-6005
SGX PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2007 2006 2007 2006
Revenue:
Collaborations
and commercial
agreements $5,722 $4,821 $11,369 $8,178
Grants 2,784 3,027 8,105 4,399
Total revenue 8,506 7,848 19,474 12,577
Expenses:
Research and development 10,524 14,956 20,542 27,007
General and administrative 2,126 2,488 4,359 5,556
Total operating expenses 12,650 17,444 24,901 32,563
Loss from operations (4,144) (9,596) (5,427) (19,986)
Interest income
(expense), net 131 242 316 217
Net loss (4,013) (9,354) (5,111) (19,769)
Accretion to
redemption value of
redeemable convertible
preferred stock - 0 - (49)
Net loss
attributable to
common
stockholders $(4,013) $(9,354) $(5,111) $(19,818)
Basic and diluted
net loss per share
attributable to common
stockholders $(0.26) $(0.62) $(0.33) $(1.60)
Shares used to
compute basic and
diluted net loss per share
attributable to common
stockholders 15,337 15,035 15,281 12,392
Three Months Ended June 30, Three Months Ended June 30,
2007 (1) 2006 (1)
Stock-based Stock-based
compen- Reported compen- Reported
sation GAAP sation GAAP
non-GAAP expense results non-GAAP expense results
Net loss
attributable to
common
stockholders $(2,911) $(1,102) $(4,013) $(8,042) $(1,312) $(9,354)
Basic and diluted
net loss per
share attributable
to common
stockholders $(0.19) $(0.07) $(0.26) $(0.53) $(0.09) $(0.62)
Research and
development
expenses $9,975 $549 $10,524 $14,374 $582 $14,956
General and
administrative
expenses $1,573 $553 $2,126 $1,758 $730 $2,488
Six Months Ended June 30, Six Months Ended June 30,
2007 (1) 2006 (1)
Stock-based Stock-based
compen Reported compen- Reported
sation GAAP sation GAAP
non-GAAP expense results non-GAAP expense results
Net loss
attributable to
common
stockholders $(3,020) $(2,091) $(5,111) $(16,937) $(2,881)$(19,818)
Basic and diluted
net loss per
share attributable
to common
stockholders $(0.20) $(0.13) $(0.33) $(1.37) $(0.23) $(1.60)
Research and
development
expenses $19,492 $1,050 $20,542 $25,532 $1,475 $27,007
General and
administrative
expenses $3,318 $1,041 $4,359 $4,150 $1,406 $5,556
SGX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
June 30, December 31,
2007 2006
Assets
Cash, cash
equivalents and
short-term
investments $28,094 $33,877
Accounts
receivable 1,863 3,532
Other current
assets 1,437 1,616
Property and
equipment, net 4,460 5,435
Other assets 3,984 4,004
Total assets $39,838 $48,464
Liabilities and
stockholder's equity
Current liabilities $18,756 $21,762
Deferred revenue,
long-term 10,069 13,023
Other liabilities,
net of current portion
Stockholder's equity 10,991 13,613
Total liabilities
and stockholder's
equity $39,838 $48,464
1) In addition to disclosing financial results calculated in accordance
with generally accepted accounting principles (GAAP), this
table contains non-GAAP financial measures that exclude the effect of
non-cash stock compensation expense. The Company believes that the
presentation of results excluding non-cash stock compensation
expense provides meaningful supplemental information to both
management and investors that is indicative of the Company's core
operating results. The Company believes these non-GAAP financial
measures facilitate comparison of operating results across reporting
periods, and uses these non-GAAP financial measures when evaluating
its financial results, as well as for internal planning and
forecasting purposes. These non-GAAP financial measures should not be
considered a substitute for, or superior to, financial measures
calculated in accordance with GAAP.
SOURCE SGX Pharmaceuticals
Source: PR Newswire (August 8, 2007 - 5:00 AM EST)
News by QuoteMedia
www.quotemedia.com
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ask ADVFN Intelligence (AI)
gym gravity
16 years ago
DewDiligence
16 years ago
Hot Features
Premium
